The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma

Qiao,Hai‑Bo; Li,Jia; Lv,Lian‑Jie; Nie,Ben‑Jin; Lu,Peng; Xue,Feng; Zhang,Zhi‑Ming

doi:10.3892/mmr.2018.8408

The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma

Authors:
- Hai‑Bo Qiao
- Jia Li
- Lian‑Jie Lv
- Ben‑Jin Nie
- Peng Lu
- Feng Xue
- Zhi‑Ming Zhang
View Affiliations

Affiliations: Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China
Published online on: January 9, 2018 https://doi.org/10.3892/mmr.2018.8408
Pages: 4853-4859

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin 2 (IL-2) is an anti-cancer cytokine that stimulates T cell propagation, triggering innate and adaptive immunity. IL-2 has been used for cancer therapy and has achieved curative effects. Recombinant adenovirus p53 injection (rAd‑p53) is a gene therapeutic agent that may improve the prognosis of patients with glioblastoma (GBM). In the present study, the effect of combined IL‑2 and rAd‑p53 treatment was studied. The ability of IL‑2 to stimulate immunoregulation and the ability of p53 to induce apoptosis for GBM was researched in the GBM tumor model. In addition, the activity of IL‑2 was analyzed. The antitumor potential of IL‑2 and rAd‑p53 was studied using xenograph mice carrying GBM cells. Tumor‑specific CD4+ and CD8+ T cells were also analyzed in the GBM‑bearing models. The results demonstrated that IL‑2 and rAd‑p53 not only stimulated tumor‑specific cytotoxic T‑lymphocyte responses and increased regulatory CD4+ and cytotoxic CD8+ T cell proliferation, however additionally increased expression of apoptosis‑associated genes. The treatment with IL‑2 and rAd‑p53 resulted in tumor regression and prolonged the survival of glioma‑bearing mice. Taken together, a combination of IL‑2 and rAd‑p53 treatment combines the effects of immunotherapy and oncolytic therapy and may be a comprehensive therapeutic schedule for clinical application in future cancer therapies.

View Figures

View References

1	Lu M, Zhang X, Zhang M, Chen H, Dou W, Li S and Dai J: Non-model segmentation of brain glioma tissues with the combination of DWI and fMRI signals. Biomed Mater Eng. 26 Suppl 1:S1315, 2015–S1324. 2015.
2	Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu MF, Liu H, Kew Y, et al: T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 21:629–637. 2013. View Article : Google Scholar : PubMed/NCBI
3	Koekkoek JA, Postma TJ, Heimans JJ, Reijneveld JC and Taphoorn MJ: Antiepileptic drug treatment in the end-of-life phase of glioma patients: A feasibility study. Support Care Cancer. 24:1633–1638. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bai FL, Tian H, Yu QZ, Renl GP and Li DS: Expressing foreign genes by Newcastle disease virus for cancer therapy. Mol Biol (Mosk). 49:195–204. 2015. View Article : Google Scholar : PubMed/NCBI
5	Snyder A, Zamarin D and Wolchok JD: Immunotherapy of Melanoma. Prog Tumor Res. 42:22–29. 2015.PubMed/NCBI
6	Bai FL, Yu YH, Tian H, Ren GP, Wang H, Zhou B, Han XH, Yu QZ and Li DS: Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther. 15:1226–1238. 2014. View Article : Google Scholar : PubMed/NCBI
7	Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J and Wu C: Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI
8	Chen Y, Guo ZQ, Shi CM, Zhou ZF, Ye YB and Chen Q: Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. Int J Clin Exp Med. 8:7728–7736. 2015.PubMed/NCBI
9	Lippitz BE: Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol. 14:e218–e228. 2013. View Article : Google Scholar : PubMed/NCBI
10	Karsy M, Neil JA, Guan J, Mahan MA, Colman H and Jensen RL: A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus. 38:E42015. View Article : Google Scholar : PubMed/NCBI
11	Yamanishi Y, Boyle DL, Green DR, Keystone EC, Connor A, Zollman S and Firestein GS: p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res Ther. 7:R12–R18. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen I, Höll T, Wiestler OD and Kleihues P: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog. 8:74–80. 1993. View Article : Google Scholar : PubMed/NCBI
13	Sakai E, Rikimaru K, Ueda M, Matsumoto Y, Ishii N, Enomoto S, Yamamoto H and Tsuchida N: The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer. 52:867–872. 1992. View Article : Google Scholar : PubMed/NCBI
14	Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855–4878. 1994.PubMed/NCBI
15	Rivlin N, Brosh R, Oren M and Rotter V: Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer. 2:466–474. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yue Q, Yulong G, Liting Q, Shuai Y, Delong L, Yubao L, Lili J, Sidang L and Xiaomei W: Mutations in and expression of the tumor suppressor gene p53 in egg-type chickens infected with subgroup J avian leukosis virus. Vet Pathol. 52:1052–1066. 2015. View Article : Google Scholar : PubMed/NCBI
17	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
18	Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M and Shekouhi S: The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. Iran J Med Sci. 37:3–8. 2012.PubMed/NCBI
19	Fagin JA: Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J Endocrinol Invest. 18:140–142. 1995. View Article : Google Scholar : PubMed/NCBI
20	Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 329:1318–1327. 1993. View Article : Google Scholar : PubMed/NCBI
21	Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL and Hainaut P: Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study. J Thorac Cardiovasc Surg. 125:1121–1131. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kuczyk MA, Serth J, Hervatin C, Arndt H, Derendorf L, Thon WF and Jonas U: Detection of p53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: Possible clinical implications. World J Urol. 12:345–351. 1994. View Article : Google Scholar : PubMed/NCBI
23	Chen GX, Zheng LH, Liu SY and He XH: rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. World J Gastroenterol. 17:4289–4297. 2011. View Article : Google Scholar : PubMed/NCBI
24	Xie Q, Liang BL, Wu YH, Zhang J, Chen MW, Liu HY, Gu XF and Xu J: Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. Gene. 499:303–308. 2012. View Article : Google Scholar : PubMed/NCBI
25	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th. National Academies Press (US); Washington, DC: 2011
26	Greaves MF and Brown G: Purification of human T and B lymphocytes. J Immunol. 112:420–423. 1974.PubMed/NCBI
27	Zamarin D, Vigil A, Kelly K, Garcia-Sastre A and Fong Y: Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 16:796–804. 2009. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Thomas AA, Ernstoff MS and Fadul CE: Immunotherapy for the treatment of glioblastoma. Cancer J. 18:59–68. 2012. View Article : Google Scholar : PubMed/NCBI
30	Larsen CJ: Cellular immunotherapy and glioblastoma: A hopeful treatment? Bull Cancer. 98:4572011.PubMed/NCBI
31	Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R and Martuza RL: Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 67:9371–9379. 2007. View Article : Google Scholar : PubMed/NCBI
32	Husain SR, Behari N, Kreitman RJ, Pastan I and Puri RK: Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res. 58:3649–3653. 1998.PubMed/NCBI
33	Debinski W, Gibo DM, Obiri NI, Kealiher A and Puri RK: Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol. 16:449–453. 1998. View Article : Google Scholar : PubMed/NCBI
34	Bera TK, Viner J, Brinkmann E and Pastan I: Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res. 59:4018–4022. 1999.PubMed/NCBI
35	Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW and Vitetta ES: Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res. 51:5876–5880. 1991.PubMed/NCBI
36	Sinkovics JG and Horvath JC: Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz). 56 Suppl 1:3S–59S. 2008. View Article : Google Scholar : PubMed/NCBI
37	Yoshida Y, Sadata A, Zhang W, Saito K, Shinoura N and Hamada H: Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther. 9:2503–2515. 1998. View Article : Google Scholar : PubMed/NCBI
38	Kusnierczyk H, Pajtasz-Piasecka E, Koten JW, Bijleveld C, Krawczyk K and Den Otter W: Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother. 53:445–452. 2004. View Article : Google Scholar : PubMed/NCBI
39	Pantuck AJ and Belldegrun AS: Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer. Curr Urol Rep. 2:332001. View Article : Google Scholar : PubMed/NCBI
40	Baek S, Kim YM, Kim SB, Kim CS, Kwon SW, Kim Y, Kim H and Lee H: Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: A phase I/II trial. Cell Mol Immunol. 12:87–95. 2015. View Article : Google Scholar : PubMed/NCBI
41	Tan Y, Xu M, Wang W, Zhang F, Li D, Xu X, Gu J and Hoffman RM: IL-2 gene therapy of advanced lung cancer patients. Anticancer Res. 16:1993–1998. 1996.PubMed/NCBI
42	Gilly FN, Beaujard A, Bienvenu J, Trillet Lenoir V, Glehen O, Thouvenot D, Malcus C, Favrot M, Dumontet C, Lombard-Bohas C, et al: Gene therapy with Adv-IL-2 in unresectable digestive cancer: Phase I–II study, intermediate report. Hepatogastroenterology. 46 Suppl 1:S1268–S1273. 1999.